Drugs / INI-822
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05945537 | Sep 2023 → May 2025 overdue | metabolic dysfunction-associated steatohepatitis | Inipharm Australia Pty Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INI-822 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05945537 ↗ |
| Route | Oral | “Participants will receive INI-822 orally once daily.” NCT05945537 ↗ |